查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1765390

基因转移系统的全球市场

Gene Delivery Systems
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球基因递送系统市场规模将达到 62 亿美元

全球基因递送系统市场规模预计在2024年为43亿美元，预计到2030年将达到62亿美元，2024年至2030年的复合年增长率为6.5%。病毒基因是本报告分析的细分市场之一，预计其复合年增长率为6.9%，到分析期结束时规模将达到41亿美元。非病毒基因细分市场在分析期间的复合年增长率估计为6.2%。

美国市场规模估计为 12 亿美元，中国市场预期复合年增长率为 6.0%

美国基因递送系统市场规模预计2024年达到12亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到9.674亿美元，在2024-2030年的分析期间内，复合年增长率为6.0%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为5.8%和5.5%。在欧洲，预计德国市场的复合年增长率为4.9%。

全球基因传递系统市场－主要趋势与驱动因素摘要

什么是基因转殖系统？为什么它们对现代医学至关重要？

基因递送系统是生物技术和医学领域的重要工具，能够将遗传物质导入细胞，在分子层面上治疗各种疾病。这些系统在基因治疗、再生医学和疫苗研发中发挥关键作用，可用于治疗癌症、遗传性疾病和感染疾病等疾病。病毒载体、脂质体和奈米颗粒是最常用的基因传递系统，它们各自在不同的应用领域中发挥独特的优势。个人化医疗领域的不断发展进一步凸显了这些系统的重要性，它们能够根据个别患者的需求进行精准的基因介入。

科技创新如何推动基因转殖？

基因递送技术的进步正在彻底改变这些系统的功能和效率。非病毒递送方法的创新，例如基于 CRISPR 的方法和电穿孔技术，正在提高基因治疗的安全性和有效性。此外，能够克服传统限制（例如免疫系统活化和标靶能力有限）的合成载体的开发，正在拓展基因传递的潜在应用。奈米颗粒工程的进步使得遗传物质的递送和释放更加精准，从而减少脱靶效应并改善患者预后。这些进步使基因递送系统更加安全、有效，并适用于更广泛的医疗应用。

为什么基因治疗解决方案的需求不断增加？

基因治疗解决方案因其有望为慢性和危及生命的疾病提供持久的治疗方法，其需求正在飙升。随着遗传学和分子生物学研究的进步，越来越多的疾病可以透过基因治疗得到治疗，为此前被认为无法治癒的疾病开闢了新的治疗途径。罕见遗传疾病、癌症和某些感染疾病是基因治疗的主要目标，因此有效的基因传递系统对于成功至关重要。此外，个人化医疗的兴起正在推动能够进行特定和靶向基因修饰的递送系统的发展，这与医疗行业根据个人基因图谱定制治疗方法的目标相一致。

是什么推动了基因传递系统市场的成长？

基因递送系统市场的成长受到多种因素的推动，包括生物技术的进步、基因治疗需求的不断增长以及对个人化医疗日益增长的关注。 CRISPR 和合成载体等技术进步使得更有效率、更有针对性的基因传递方法成为可能，从而扩大了可治疗疾病的范围。随着基因治疗方案作为遗传疾病和癌症的潜在治疗方法日益受到关注，对有效递送系统的需求也日益增长。此外，对精准医疗的日益重视也要求能够针对个别患者进行特定、可控的基因介入的系统。这些因素共同作用，使基因递送系统市场成为现代医学的基石。

部分

递送（病毒基因、非病毒基因、复杂杂交）、应用（肿瘤学、中枢神经系统、感染疾病、眼科、糖尿病、其他应用）

受访公司范例

  • Amgen, Inc.
  • Bayer AG
  • Human Stem Cells Institute
  • Johnson & Johnson
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP16418

Global Gene Delivery Systems Market to Reach US$6.2 Billion by 2030

The global market for Gene Delivery Systems estimated at US$4.3 Billion in the year 2024, is expected to reach US$6.2 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Viral Gene, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Non-Viral Gene segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 6.0% CAGR

The Gene Delivery Systems market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$967.4 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Gene Delivery Systems Market - Key Trends & Drivers Summarized

What Are Gene Delivery Systems and Why Are They Essential in Modern Medicine?

Gene delivery systems are vital tools in the field of biotechnology and medicine, enabling the introduction of genetic material into cells to treat various diseases at a molecular level. These systems play a crucial role in gene therapy, regenerative medicine, and vaccine development, addressing conditions like cancer, genetic disorders, and infectious diseases. Viral vectors, liposomes, and nanoparticles are among the most commonly used methods in gene delivery systems, each offering unique benefits for different applications. The growing field of personalized medicine further underscores the importance of these systems, as they enable precise genetic interventions tailored to individual patients’ needs.

How Is Technological Innovation Advancing Gene Delivery?

Technological advancements in gene delivery are revolutionizing the capabilities and efficiency of these systems. Innovations in non-viral delivery methods, such as CRISPR-based approaches and electroporation, are increasing the safety and efficacy of gene therapies. Additionally, the development of synthetic vectors that can overcome traditional limitations, such as immune system activation and limited targeting capabilities, is expanding the potential applications of gene delivery. Advances in nanoparticle engineering allow for more precise delivery and controlled release of genetic material, reducing off-target effects and improving patient outcomes. These advancements are making gene delivery systems safer, more effective, and suitable for a broader range of medical applications.

Why Is There Growing Demand for Gene Therapy Solutions?

The demand for gene therapy solutions is surging due to their potential to offer lasting cures for chronic and life-threatening conditions. As research in genetics and molecular biology progresses, more diseases are becoming treatable through gene therapy, opening new avenues for conditions previously considered incurable. Rare genetic disorders, cancers, and certain infectious diseases are prime targets for gene therapy, where effective gene delivery systems are essential to success. Additionally, with the rise in personalized medicine, there is a push for delivery systems that allow specific, targeted genetic modifications, aligning with the healthcare industry’s goal of creating treatments tailored to individual genetic profiles.

What Drives the Growth of the Gene Delivery Systems Market?

The growth in the gene delivery systems market is driven by several factors, including advancements in biotechnology, increasing demand for gene therapies, and the rising focus on personalized medicine. Technological progress, such as CRISPR and synthetic vector development, has enabled more efficient and targeted gene delivery methods, expanding the range of treatable diseases. The need for effective delivery systems is growing as gene therapy solutions gain traction as potential cures for genetic disorders and cancers. Furthermore, the emphasis on precision medicine is pushing for systems that allow for specific, controlled genetic interventions tailored to individual patients. Collectively, these factors are propelling the gene delivery systems market forward as it becomes a cornerstone in modern medicine.

SCOPE OF STUDY:

The report analyzes the Gene Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Delivery (Viral Gene, Non-Viral Gene, Combined Hybrid); Application (Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

  • Amgen, Inc.
  • Bayer AG
  • Human Stem Cells Institute
  • Johnson & Johnson
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Tariff Impact on Global Supply Chain Patterns
    • Gene Delivery Systems - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Gene Therapy in Treating Genetic Disorders
    • Advancements in Viral and Non-Viral Gene Delivery Technologies
    • Increased Focus on Targeted and Precision Medicine for Enhanced Therapeutic Efficacy
    • Expansion of Gene Delivery Applications in Oncology and Rare Diseases
    • Growing Adoption of CRISPR and Other Gene Editing Tools for Gene Therapy
    • Surge in Research Funding for Developing Novel Gene Delivery Methods
    • Increased Demand for Safer and More Efficient Gene Delivery Vehicles
    • Development of Nanoparticle-Based Gene Delivery Systems for Better Bioavailability
    • Rising Investment in Gene Delivery for Regenerative Medicine and Cell Therapy
    • Expansion of Clinical Trials Investigating Gene Delivery for Neurological Disorders
    • Growth in Partnerships Between Biotech Firms and Academic Institutions
    • Focus on Improving Patient Outcomes and Reducing Side Effects in Gene Therapy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gene Delivery Systems Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gene Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gene Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Gene Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Viral Gene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Viral Gene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combined Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combined Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Combined Hybrid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for CNS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Gene Delivery Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Gene Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of World 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of World 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION